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To estimate time to first optimal glycaemic control and identify prognostic factors among
type 2 diabetes mellitus (T2DM) patients attending diabetes clinic of public teaching hospi-
tals in Addis Ababa, Ethiopia.
Methods
A retrospective chart review study was conducted at diabetes clinic of Addis Ababa’s public
teaching hospitals among a randomly selected sample of 685 charts of patients with
T2DMwho were on follow up from January 1, 2013 to June 30, 2017. Data was collected
using data abstraction tool. Descriptive statistics, Kaplan Meier plots, median survival time,
Log-rank test and Cox proportional hazard survival models were used for analysis.
Results
Median time to first optimal glycaemic control among the study population was 9.5 months.
Factors that affect time to first optimal glycaemic control were age group (HR = 0.635, 95%
CI: 0.486–0.831 for 50–59 years, HR = 0.558, 95% CI: 0.403–0.771for 60–69 years and HR
= 0.495, 95% CI: 0.310–0.790 for > = 70 years), diabetes neuropathy (HR = 0.502, 95% CI:
0.375–0.672), more than one complication (HR = 0.381, 95% CI: 0.177–0.816), hyperten-
sion (HR = 0.611, 95% CI: 0.486–0.769), dyslipidemia (HR = 0.609, 95% CI: 0.450–0.824),
cardiovascular disease (HR = 0.670, 95% CI: 0.458–0.979) and hospital patient being
treated (HR = 1.273, 95% CI: 1.052–1.541).
Conclusions
Median time to first optimal glycaemic control among T2DM patients is longer than expected
which might imply that patients are being exposed to more risk of complication and death.
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Introduction
Diabetes is a chronic, progressive disease characterized by elevated levels of blood glucose.
There are three types of diabetes: Type 1, Type2 and gestational diabetes. Type 2 diabetes is the
commonest type[1, 2].
Diabetes is one of the largest global health emergencies of the 21st century. Each year more
and more people live with this condition and this increase is noted more rapidly in resource
limited countries. According to IDF Atlas and WHO, about 45.1% of all adults aged 20–79
years with diabetes in Africa live in four countries including Ethiopia. In Ethiopia, prevalence
of diabetes in adults has increased from 2.9% in 2015 to 3.8% in 2016 to 5.2% in 2017[3–5].
People with diabetes can live longer and have a healthy life if their diabetes is detected early
and well-managed, with integrated self-management and health professional support. The lon-
ger a person lives with undiagnosed, untreated and/or uncontrolled diabetes, the worse their
health outcomes are likely to be. Therefore, controlling blood glucose is key in preventing and
slowing the progression of complications [1–4].
Studies conducted in different regions of Ethiopia have focused mainly on level of glycae-
mic control at one point in time. Majority of the studies show poor glycaemic control (60–80%
patients in each study have poor glycaemic control) [6–9]. This is also the case in other coun-
tries including Uganda, Kenya, India and China [10–13]. Similarly, a systematic review of liter-
atures from 2011–2015 shows that glycaemic control is suboptimal in majority (typically 40%-
60%) of people with diabetes in both low- and higher-income countries [14].
In addition, studies conducted among T2DM patients who has been followed over a period
of time has shown that old age, being overweight, long-standing diabetes, high HgA1c, LDL-
to-HDL cholesterol ratios, hypertension, micro-albuminuria, and previous cardiovascular dis-
ease, are important predictors of poor glycaemic control, morbidity and mortality [12, 15–17].
Though knowing the level of glycaemic control of a patient is an important predictor of
development of complication and risk of death from diabetes, the other most important pre-
dictor which is the time that the patient stayed in that poor glycaemic level before reaching
optimal glycaemic control has not been studied yet.
Patients with same level of poor glycaemic control can have different prognosis because of
the difference in the time the patients stayed in that poor glycaemic state. The risk of complica-
tion and death increases as the patient stays longer in poor glycaemic level.
The objective of this study was to estimate time to first optimal glycaemic control and iden-
tify prognostic factors among T2DM patients attending diabetes clinic of public teaching hos-
pitals in Addis Ababa, Ethiopia.
Methods and materials
2.1 Study design and subjects
The study design was hospital-based retrospective chart review and was conducted at two pub-
lic teaching hospitals in Addis Ababa: St Paul Hospital Millennium Medical College
(SPHMMC) and Yekatit 12 Hospital Medical College (Y12HMC). Both hospitals have a diabe-
tes clinic which is under the department of internal medicine. At Y12HMC patients are seen
mainly by General Practitioners (GP) and internists. There was no endocrinologist in the hos-
pital during the study period. At SPHMMC patients are seen by internal medicine residents,
internists and endocrinologist. The hospitals do not use the national diabetes management
intake and follow up guideline consistently. Medical records and information sheets of new
T2DM patients’ who were on follow up from 1stJanuary, 2013 to 31stDecember, 2017 was
reviewed.
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2.2 Source and Study population
The source population was all new T2DM patients who were on follow up at diabetes clinic of
the two hospitals from January 1, 2013 to June 30, 2017. During this interval a total of 1,508
new patients were seen at the two hospitals: 923 patients at SPHMMC and 585 patients at
Y12HMC.
The study population was all selected new T2DM patients who full fill the inclusion criteria
of>18 years and non-pregnant.
2.3 Sample size and sampling procedure
Sample size was determined by using sample size calculation formula forsurvival analysis by
considering the following statistical assumptions: 95% Confidence Interval (CI), power of
90%, survival probability of 0.5, 5% marginal error, and loss of 20%. The final sample size for
this study was 783.
The estimated total sample size was proportionally allocated to the two study sites accord-
ing to the number of eligible participants in each site. Finally, cards of 417 from SPHMMC
and 269 from Y12HMC that fulfilled the criteria were randomly selected and reviewed.
2.4 Operational definitions
Optimal glycaemic control. Optimal glycaemic control is defined as the three consecutive
month average fasting blood glucose of 80–130 mg/dl with more or less stringent glycemic
goals for individual patients based on age/ life expectancy, comorbid conditions, advanced
microvascular complications, hypoglycemia unawareness, and individual patient consider-
ations[18]. N.B: FBS is used as a follow up tool in our set up because HgA1c is not consistently
available for patient diagnosis and follow up.
Event. achieving first optimal glycaemic control.
Censoring. patients died, lost to follow-up, transferred out and completed the follow-up
period without achieving optimal glycaemic control.
Time to event. time between diagnosis up to achieving first optimal glycaemic control or
censoring (in month).
• Start date of the study:1stJanuary, 2013
• End date of the study:31stDecember, 2017
2.5 Data collection
Pre-tested data abstraction tool (questionnaire) that consists of questions to assess the relevant
variables was used to collect the necessary data from the patient medical chart by trained data
collectors.
2.6 Statistical analysis
The collected data was coded and entered into Epi-Info version 7.2.1.0, cleaned, stored and
exported into SPSS version 23 for analysis. Descriptive statistics was presented with frequency
tables, Kaplan Meier (KM) plots and median survival times. Kaplan-Meier technique was used
to assess survival experience of different groups of patients by using survival curves. Log-rank
test was used to assess significant difference among survival distributions of groups for
equality.
Univariate analysis was performed to calculate an unadjusted hazard ratio (HR) and to
screen out potentially significant independent variables at 25% level of significance.
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Association between the significant independent variables and the time to first optimal glycae-
mic control was assessed using multivariable Cox Proportional Hazard (PH) model. Adjusted
hazard ratio (HR), P-value and 95% CI for HR were used to test significance and interpretation
of results. Variables with p-value� 0.05 were considered as statistically associated with the
time to first optimal glycaemic control in months.
2.7 Ethical considerations
The study was conducted after obtaining ethical clearance from GAMBY Medical and Business
College IRB, Addis Ababa Health Bureau, Y12HMC and SPHMMC. Written informed con-
sent was obtained from Endocrinology or Internal medicine department of the hospitals on
behalf of the patients. The study had no any risk/negative consequence for study participants.
Medical record number was used for the data collection and personal identifiers of the patient
were not used in the research report. Access to the collected information was limited to the
principal investigator and confidentiality was maintained throughout the project.
Result
3.1 Censoring status
Among the 685 patients, 483 (70.5%) of the patients achieved optimal glycaemic control while
202 (29.5%) were censored. The median time to achieving optimal glycaemic control was 9.5
months.
3.2 Socio-demographic and institution related variables and censoring
status
Majority of the patients (27.7%) were in the age range of 50–59 years, 54.6% of the patients
were females and majority of the patients were from Addis Ababa (73.7%). More than half
(60.9%) of the patients were from SPHMMC and the rest (39.1%) were from Y12HMC.
Higher proportion of patients in the age group 30–39 achieved optimal glycaemic control,
followed by 40–49, 50–59, 60–69 and > = 70 years age groups.
The proportion of patients who achieved optimal glycaemic control among females (73.5%)
is higher than males (66.9%). Almost seventy percent (69.9%) of patients from Addis Ababa
has achieved optimal glycaemic control. The proportion of patients who achieved optimal gly-
caemic control at SPHMMC (74.1%) is higher than Y12HMC (64.9%). (Table 1)
3.3 Diabetes related variables (diabetes related complications, diabetes
hospitalization and medication) and censoring status
Regarding history of diabetes related complication in general, 32.0% of the patients had history
of one or more complications. Majority of the patients had neuropathy (16.9%) followed by
acute complication (12.7%), nephropathy (5.1%) and other complication (3.8%). Eighty seven
(12.6%) patients had diabetes related hospitalization which was mainly due to acute complica-
tion. Oral anti-diabetic drug was given to the majority of patients at the initiation of treatment
(83.5%) compared to insulin (16.5%).
The proportion of patients who achieved optimal glycaemic control is higher among those
with no history of diabetes related complication (75.8%) compared to those with one or more
complication (59.4%).
The proportion of patients who achieved the event is lower among those with more than
one diabetes related complication (22.0%) compared to those with only one complication or
no complication (73.6%).
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The proportion of patients who achieved optimal glycaemic control is comparable among
those who were on oral anti-diabetic drug and insulin at the time of initiation of treatment
(70.3% Vs 71.7%). (Table 2)
3.4 Co- morbid illness and censoring status
More than half (58.8%) of the patients had history of co-morbid illness and 41.2% did not
have. Majority of the patients had hypertension (48.6%) followed by dyslipidemia (22.6%), car-
diovascular disease (13.9%) and other co-morbid illness (11.1%). More than one fourth of
patients (27.6%) had more than one co morbid illness.
The proportion of patients who achieved optimal glycaemic control is higher among those
with no history of co-morbid illness (80.9%) than those with one or more co-morbid illness
(63.3%). (Table 3)
Table 1. Socio–demographic and institution related variables and censoring status among T2DM patients, Addis Ababa, 2018 (n = 685).
Variable Category Censoring status Total (%)
No censored (%) No of event (%)
Age group in years 30–39 24 (15.6%) 130 (84.4%) 154 (22.5%)
40–49 36 (22.1%) 127 (77.9%) 163 (23.8%)
50–59 62 (32.6%) 128 (67.4%) 190 (27.7%)
60–69 50 (41.0%) 72 (59.0%) 122 (17.8%)
> = 70 30 (53.6%) 26 (46.4%) 56 (8.2%)
Sex Female 99 (26.5%) 275 (73.5%) 374 (54.6%)
Male 103 (33.1%) 208 (66.9%) 311 (45.4%)
Region Addis Ababa 152 (30.1%) 353 (69.9%) 505 (73.7%)
Outside Addis Ababa 50 (27.8%) 130 (72.2%) 180 (26.3%)
Hospital Yekatit 12 94 (35.1%) 174 (64.9%) 268 (39.1%)
St Paul 108 (25.9%) 309 (74.1%) 417 (60.9%)
https://doi.org/10.1371/journal.pone.0220309.t001
Table 2. Diabetes related variables and censoring status among T2DM patients, Addis Ababa, 2018 (n = 685).
Variable Category Censoring status Total (%)
No censored (%) No of event (%)
History of diabetes related complication No 113 (24.2%) 353 (75.8%) 466 (68.0%)
Yes 89 (40.6%) 130 (59.4%) 219 (32.0%)
Acute complication No 173 (28.9%) 425 (71.1%) 598 (87.3%)
Yes 29 (33.3%) 58 (66.7%) 87 (12.7%)
Diabetes nephropathy No 176 (27.1%) 474 (72.9%) 650 (94.9%)
Yes 26 (74.3%) 9 (25.7%) 35 (5.1%)
Diabetes neuropathy No 145 (25.5%) 424 (74.5%) 569 (83.1%)
Yes 57 (49.1%) 59 (50.9%) 116 (16.9%)
Other complication� No 189 (28.7%) 470 (71.3%) 659 (96.2%)
Yes 13 (50.0%) 13 (50.0%) 26 (3.8%)
More than one complication No 170 (26.4%) 474 (73.6%) 644 (94.0%)
Yes 32 (78.0%) 9 (22.0%) 41 (6.0%)
Diabetes related hospitalization No 170 (28.4%) 429 (71.6%) 599 (87.4%)
Yes 32 (37.2%) 54 (62.8%) 86 (12.6%)
Regimen Oral 170 (29.7%) 402 (70.3%) 572 (83.5%)
Insulin 32 (28.3%) 81 (71.7%) 113 (16.5%)
�Other complication includes diabetes retinopathy, diabetic foot ulcer and diabetes gastropathy
https://doi.org/10.1371/journal.pone.0220309.t002
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3.5 Comparison of survival experience
A log rank test was used to assess difference in the survival distribution among groups. The
median survival time showed that females achieved optimal glycaemic control in a relatively
shorter time (8.6 months) than males (10.3 months). The log rank test was statistically signifi-
cant (X2(1) = 5.546, P-value = 0.019). As shown in Fig 1 the KM survival function graph also
showed that females have a favorable survival (time to achievement of first optimal glycaemic
control) experience. The figure shows that, the instantaneous chance of achieving optimal gly-
caemic control increases for both sexes as the duration of treatment increases.
Regarding age, patients in the age group of 30–39 years showed shorter median time to
achieving optimal glycaemic control (5.2 months) followed by patients in the age group 40–49
years (6.5 months). Older patients needed much longer time to achieve optimal glycaemic con-
trol; 10.8 months for 50–59 years, 14.8 months for 60–69 years and 28.6 months for > = 70
yearsof age. The survival time was significantly different among the five age groups (X2(4) =
129.010, P-value = 0.000).
Having complications seems to extend time to achieve optimal glycaemic control. The aver-
age time to achieve optimal glycaemic control was longer among patients with nephropathy
(36.5 months) followed by patients with neuropathy (21.7 months) and other complication
(18.7 months) and all show statistically significant (all p-values <0.05) difference when com-
pared to the average time of patients with no such complications.
The median time to achieving optimal glycaemic control was longer among patients with
cardiovascular disease (20.9 months), those with more than one co-morbid illness (18.4
months), dyslipidemia (16.6 months), other co-morbid illness (16.0 months) and hypertension
(14.8 months) and all show statistically significant (all p-values<0.05) difference when com-
pared to the median time of patients with no such complications.
The median time to achieving optimal glycaemic control among patients who has been hos-
pitalized is longer (10.7 months) than those who has not been hospitalized (9.7 months) and it
was statistically significant (X2(1) = 3.947, P-value = 0.047). (Table 4)
3.6 Results of multivariable cox proportional hazard model
The fundamental assumption of Cox Proportional Hazard model, proportional hazards
assumption, was tested using Log minus Log function on STATA version 14. Parallel lines
Table 3. Co-morbid illness and censoring status among T2DM patients, Addis Ababa, 2018 (n = 685).
Variable Category Censoring status Total (%)
No censored (%) No of event (%)
History of co-morbid illness No 54 (19.1%) 228 (80.9%) 282 (41.2%)
Yes 148 (36.7%) 255 (63.3%) 403 (58.8%)
Hypertension No 75 (21.3%) 277 (78.7%) 352 (51.4%)
Yes 127 (38.1%) 206 (61.9%) 333 (48.6%)
Dyslipidemia No 135 (25.5%) 395 (74.5%) 530 (77.4%)
Yes 67 (43.2%) 88 (56.8%) 155 (22.6%)
Cardiovascular disease No 152 (25.8%) 438 (74.2%) 590 (86.1%)
Yes 50 (52.6%) 45 (47.4%) 95 (13.9%)
Other co-morbid illness� No 175 (28.7%) 434(71.3%) 609 (88.9%)
Yes 27 (35.5%) 49 (64.5%) 76 (11.1%)
More than one co morbid illness No 114 (23.0%) 382 (77.0%) 496 (72.4%)
Yes 88 (46.6%) 101 (53.4%) 189 (27.6%)
Others�: includes renal disease, neurologic disease, chronic respiratory diseases and thyroid metabolism disorders
https://doi.org/10.1371/journal.pone.0220309.t003
Time to optimal glycaemic control among T2DM patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0220309 July 31, 2019 6 / 12
between groups indicate proportionality [19]. Fig 2 reveals that the survival curves seem paral-
lel throughout the study time. These plots show reasonable fit to the proportional hazard
assumption.
From univariate analysis of the independent variables at 25% level of significance; sex, age
group, diabetes neuropathy, other complication, more than one complication, hypertension,
dyslipidemia, cardiovascular disease, other co-morbid illness, more than one co-morbid ill-
ness, diabetes related hospitalization and hospital patient being treated were significantly asso-
ciated with time to optimal glycaemic control among T2DM patients.
However; only age group, diabetes neuropathy, more than one complication, hypertension,
dyslipidemia, cardiovascular disease and hospital patient being treated were found to be signif-
icantly associated with time to optimal glycaemic control in the multivariable Cox propor-
tional hazard model at 5% level of significance.
The presence of interaction among the independent variables was checked but there was no
significant interaction.
Accordingly, after adjusting for other covariates, compared to those in the age range of 30–
39 years, the rate of achieving optimal glycaemic control among those in the age group 50–59,
60–69 and > = 70 years were lower by 36.5%, 44.2% and 50.5%, respectively.
The rate of achieving optimal glycaemic control among patients with neuropathy was lower
by 49.8% compared to patients with no neuropathy (HR = 0.502, 95% CI = 0.375–0.672, p-
value = 0.000). This means, the time needed to reach optimal glycaemic control among
patients with no neuropathy was significantly shorter compared with patients with
neuropathy.
Similarly, the rate of achieving optimal glycaemic control among patients with more than
one complication was 62% lower than patients with no or one complication (HR = 0.381, 95%
CI = 0.177–0.816, p-value = 0.013).
Regarding presence of co-morbid illness, after adjusting for other covariates, the rate of
achieving optimal glycaemic control among patients with hypertension, dyslipidemia and car-
diovascular disease were respectively lower by 38.9%, 39.1% and 33.0% compared to patients
with no hypertension, dyslipidemia and cardiovascular disease.
Fig 1. Survival and hazard functions of sex by time, Addis Ababa, 2018.
https://doi.org/10.1371/journal.pone.0220309.g001
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The rate of achieving optimal glycaemic control among patients treated at SPHMMC is
1.273 times patients treated at Y12HMC (HR = 1.273, 95% CI = 1.052–1.541, p-value = 0.013).
(Table 5)
Discussion
In our study, the median time to achieving optimal glycaemic control was 9.5 months. Though
no clear cut off point is set about when to reach optimal glycaemic control, the trend is to have
frequent visits and strict follow up for a newly diagnosed T2DM patient till the patient achieves
optimal glycaemic control. Therefore, with the measurement tool that we are using for the
Table 4. Comparison of optimal glycaemic control among T2DM patients, Addis Ababa, 2018 (n = 685).
Variable Category Test of equality over groups
Median survival time(months) Mean survival time(months) Log rank (mantel cox)
Chi square Df Pr>chi square




> = 70 17.0 28.6
Sex Female 8.6 14.3 5.546 1 0.019
Male 10.3 17.2
Region Addis Ababa 9.9 16.1 1.241 1 0.265
Outside Addis Ababa 8.3 14.1
Hospital patient being treated Yekatit 12 10.3 17.6 2.988 1 0.084
St. Paul 8.7 14.4
Diabetes related acute complication No 9.5 15.3 0.140 1 0.708
Yes 9.5 18.3
Diabetes nephropathy No 8.9 14.6 29.448 1 0.000
Yes 36.5 35.3
Diabetes neuropathy No 7.8 13.0 58.926 1 0.000
Yes 21.7 27.3
Other complication No 9.0 15.1 11.515 1 0.001
Yes 18.7 27.8
Hypertension No 5.7 10.5 110.599 1 0.000
Yes 14.8 20.9
Dyslipidemia No 7.6 13.5 45.642 1 0.000
Yes 16.6 23.0
Cardiovascular disease No 7.9 13.7 44.292 1 0.000
Yes 20.9 27.3
Other co-morbid illness No 8.5 14.8 14.475 1 0.000
Yes 16.0 22.0
More than one co-morbid illness No 6.9 11.4 105.090 1 0.000
Yes 18.4 25.9
Diabetes related hospitalization No 9.4 14.7 3.947 1 0.047
Yes 10.7 20.9
Regimen Oral 9.7 15.2 0.009 1 0.924
Insulin 8.7 16.3
https://doi.org/10.1371/journal.pone.0220309.t004
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study, three consecutive months average fasting blood sugar, patients are expected to reach tar-
get at the 3rd month or may be a bit longer than that.
Since there is no previous similar study, the results of this study is compared with cross sec-
tional studies on optimal glycaemic control and survival studies with the event of interest
being death and diabetes related morbidity and mortality. The identified prognostic factors of
this study are found to be analogous with these literatures.
The age of patients is found to be an important factor that determines time to first optimal
glycaemic control. The study shows that the time needed to reach first optimal glycaemic con-
trol doesn’t show significant difference between 30–39 and 40–49 years of age. This may be
due to the fact that relatively younger patients (30–39 and 40–49) have less co-morbid illness
that can affect diabetes disease prognosis and there chance of adherence to follow up and treat-
ment is thought to be relatively better. On the other hand, time needed to reach optimal gly-
caemic control is longer among patients > = 70 years followed by the age group 60–69 and
50–59 years compared to patients in 30–39 years age group indicating that for patients older
than 50 years, as age increases the rate of achieving optimal glycaemic control decreases. This
finding is in line with studies conducted in Charleston, South Carolina and India[12, 17].
The study found that having diabetes related complication particularly neuropathy and
having more than one diabetes related acute or chronic complication is an important prognos-
tic factor. Patients with neuropathy and more than one complication tend to achieve optimal
glycaemic control at a rate of 49.8% and 62% lower that of patients with no neuropathy and
patients with no or one complication. This is in accordance with a study conducted at Yekatit
12 hospital and Nantong University hospital [10, 15, 20].
In addition, having co-morbid illness is found to be an important prognostic factor that
affects time to optimal glycaemic control. The rate of achieving optimal glycaemic control
among patients with hypertension, dyslipidemia and cardiovascular disease were lower by
38.9%, 39.1% and 33.0% compared with patients with no such illnesses showing that dyslipide-
mia has a more negative influence on individual diabetes control followed by hypertension
and then cardiovascular disease. This is because having co-morbid illness has effect on diabetes
disease progress and could also be due to the effect of taking many drugs which can lead to
drug interaction and also decreased drug adherence which interferes with drug effectiveness.
Fig 2. Log minus Log function for hospital and sex, 2018, Addis Ababa.
https://doi.org/10.1371/journal.pone.0220309.g002
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This finding is in line with studies conducted in Charleston, South Carolina, Sweden,Yekatit
12 hospital, Arabian Gulf council countries and Kenya [13, 15–17, 21].
Our study also identified hospital where T2DM patients were treated as one of the factors
significantly associated with time to first optimal glycaemic control. The rate of achieving
Table 5. Results for the final Cox proportional hazard model among T2DM patients,Addis Ababa, 2018(n = 685).
Variables HR (Exp(B) 95.0% CI for HR Sig.
Age in years
30–39 (R) 0.001�
40–49 0.808 (0.627, 1.042) 0.101
50–59 0.635 (0.486, 0.831) 0.001
60–69 0.558 (0.403, 0.771) 0.000
> = 70 0.495 (0.310, 0.790) 0.003
Sex
Female (R) 1
Male 0.838 (0.698, 1.007) 0.059
Diabetes neuropathy
No (R) 1
Yes 0.502 (0.375, 0.672) 0.000�
Other complication
No (R) 1
Yes 0.634 (0.340, 1.184) 0.153
More than one complication
No (R) 1
Yes 0.381 (0.177, 0.816) 0.013�
Hypertension
No (R) 1
Yes 0.611 (0.486, 0.769) 0.000�
Dyslipidemia
No (R) 1
Yes 0.609 (0.450, 0.824) 0.001�
Cardiovascular disease
No (R) 1
Yes 0.670 (0.458, 0.979) 0.039�
Other co-morbid illness
No (R) 1
Yes 0.705 (0.490, 1.014) 0.059
More than one co-morbid illness
No (R) 1
Yes 0.891 (0.589, 1.347) 0.583
Hospital patient being treated
Yekatit 12 (R) 1
St Paul 1.273 (1.052, 1.541) 0.013�
Diabetes related hospitalization
No (R) 1
Yes 0.791 (0.587, 1.065) 0.122
Note: HR, Hazard ratio; CI, Confidence interval
� Statistically significant
https://doi.org/10.1371/journal.pone.0220309.t005
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optimal glycaemic control among patients at SPHMMC is 27.3% higher than patients at
Y12HMC. This difference could be because of difference in underlying population characteris-
tics or unequal sample sizes of the two hospitals, the sample size from SPHMMC was more
than 1.5 times the sample size of Y12HMC (268). It could also be due to difference in the level
of health professionals who work at the diabetes clinics as having more professional experience
and better exposure and training might be an important contributor for better patient manage-
ment. The other contributing factor could be the non-consistent use of the national diabetes
management and follow up guideline. Using the guideline might help the professionals to
address all the relevant factors in patient management in a consistent way and might result
comparable outcome between the hospitals.
Conclusion
Median time to first optimal glycaemic control among T2DM patients attending diabetes
clinic of Y12HMC and SPHMMC is longer than expected which might imply that patients are
being exposed to more risk of complication and death. This increased risk remains higher for
these patients even after they achieved optimal glycaemic control compared to those who
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